New and emerging treatments for ulcerative colitis: A focus on vedolizumab

Biologics: Targets and Therapy

Volumn 7, Issue 1, 2013, Pages 123-130

  Gledhill, Tamsin ^a   Bodger, Keith ^b  

^a UNIVERSITY HOSPITAL AINTREE   (United Kingdom)

^b UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

Effectiveness; Inflammatory bowel disease; Integrin antagonists

Indexed keywords

6 MERCAPTOPURINE DERIVATIVE; ADALIMUMAB; AGENTS USED IN INFLAMMATORY BOWEL DISEASE; ALPHA4BETA7 INTEGRIN; CORTICOSTEROID; CYCLOSPORIN; GLUCOCORTICOID; INFLIXIMAB; INTEGRIN; INTEGRIN ANTAGONIST; MESALAZINE; METHOTREXATE; MLN 002; MUCOSAL ADDRESSIN CELL ADHESION MOLECULE 1; NATALIZUMAB; PLACEBO; UNCLASSIFIED DRUG; VEDOLIZUMAB;

ANGIONEUROTIC EDEMA; ANTIBODY RESPONSE; COMBINATION CHEMOTHERAPY; CROHN DISEASE; CYTOMEGALOVIRUS INFECTION; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EVIDENCE BASED MEDICINE; GASTROENTERITIS; HUMAN; IMMUNOGENICITY; IMMUNOSUPPRESSIVE TREATMENT; INFUSION RELATED REACTION; MAINTENANCE THERAPY; NONHUMAN; PATHOGENESIS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REMISSION; REVIEW; RHINOPHARYNGITIS; RISK FACTOR; ULCERATIVE COLITIS; UNSPECIFIED SIDE EFFECT; URTICARIA;

EID: 84878173297     PISSN: 11775475     EISSN: 11775491     Source Type: Journal    
DOI: 10.2147/BTT.S30416     Document Type: Review

References (41)

1. Ordás I, Eckmann L, Talamini M, Baumgart DC, Sandborn WJ. Ulcerative colitis. Lancet. 2012;380(9853):1606-1619.
2. D'Haens G, Sandborn WJ, Feagan BG, et al. A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis. Gastroenterology. 2007;132(2):763-786.
3. Dignass A, Lindsay JO, Sturm A, et al. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 2: current management. J Crohns Colitis. 2012;6(10):991-1030.
4. Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005; 353(23):2462-2476.
5. Reinisch W, Sandborn WJ, Hommes DW, et al. Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial. Gut. 2011;60(6):780-787.
6. Taxonera C, Estellés J, Fernández-Blanco I, et al. Adalimumab induction and maintenance therapy for patients with ulcerative colitis previously treated with infliximab. Aliment Pharmacol Ther. 2011;33(3): 340-348.
7. McDermott E, Murphy S, Keegan D, O'Donoghue D, Mulcahy H, Doherty G. Efficacy of Adalimumab as a long term maintenance therapy in ulcerative colitis. J Crohns Colitis. Epub April 18, 2012.
8. Danese S. New therapies for inflammatory bowel disease: from the bench to the bedside. Gut. 2012;61(6):918-932.
9. Behm BW, Bickston SJ. Humanized antibody to the alpha4beta7 integrin for induction of remission in ulcerative colitis. Cochrane Database Syst Rev. 2009;1:CD007571.
10. Tilg H, Kaser A. Vedolizumab, a humanized mAb against the α4β7 integrin for the potential treatment of ulcerative colitis and Crohn's disease. Curr Opin Investig Drugs. 2010;11(11):1295-1304.
11. Souza HS, Elia CC, Spencer J, MacDonald TT. Expression of lymphocyte-endothelial receptor-ligand pairs, alpha4beta7/MAdCAM-1 and OX40/OX40 ligand in the colon and jejunum of patients with inflammatory bowel disease. Gut. 1999;45(6):856-863.
12. Arihiro S, Ohtani H, Suzuki M, et al. Differential expression of mucosal addressin cell adhesion molecule-1 (MAdCAM-1) in ulcerative colitis and Crohn's disease. Pathol Int. 2002;52(5-6):367-374.
13. Meenan J, Spaans J, Grool TA, Pals ST, Tytgat GN, van Deventer SJ. Altered expression of alpha 4 beta 7, a gut homing integrin, by circulating and mucosal T cells in colonic mucosal inflammation. Gut. 1997;40(2):241-246.
14. Monteleone G, Caprioli F. Why are molecular mechanisms of immune activation important in IBD? Inflam Bowel Dis. 2008;14 Suppl 2: S106-S107.
15. Caviglia R, Boskoski I, Cicala M. Maintenance treatment with infliximab for the management of Crohn's disease in adults. Biologics. 2009;3:39-49.
16. Cassinotti A, Ardizzone S, Porro GB. Adalimumab for the treatment of Crohn's disease. Biologics. 2008;2(4):763-777.
17. Marshall JK. LDP-02 (Millenium). Curr Opin Investig Drugs. 2001; 2(4):502-504.
18. Hesterberg PE, Winsor-Hines D, Briskin MJ, et al. Rapid resolution of chronic colitis in the cotton-top tamarin with an antibody to a gut-homing integrin alpha 4 beta 7. Gastroenterology. 1996;111(5): 1373-1380.
19. van Assche G, Rutgeerts P. Antiadhesion molecule therapy in inflammatory bowel disease. Inflam Bowel Dis. 2002;8(4):291-300.
20. Feagan B, Macdonald J, Greenberg G, et al. An ascending dose of a humanized alpha 4 beta 7 antibody in ulcerative colitis (UC). Gastroenterology. 2000;118(4):A874.
21. Baron JH, Cornell AM, Lennard-Jones JE. Variation between observers in describing mucosal appearances in proctocolitis. BMJ. 1964;11(1):89-92.
22. Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminoscilyclic- acid therapy for mild to moderately active ulcerative colitis. New England Journal of Medicine. 1987;317(26):1625-1629.
23. Feagan BG, Greenberg GR, Wild G, et al. Treatment of ulcerative colitis with a humanized antibody to the alpha4beta7 integrin. N Engl J Med. 2005;352(24):2499-2507.
24. Parikh A, Leach T, Wyant T, et al. Vedolizumab for the treatment of active ulcerative colitis: a randomized controlled phase 2 dose-ranging study. Inflam Bowel Dis. 2011;18(8):1470-1479.
25. National Institute for Health and Clinical Excellence (NICE). Infliximab for Acute Exacerbations of Ulcerative Colitis. NICE technology appraisal guidance 163. London: NICE; 2008 [updated 2011]. Available from: http://www.nice.org.uk/nicemedia/pdf/TA163Guidance.pdf. Accessed January 22, 2013.
26. NICE. Infliximab for Subacute Manifestations of Ulcerative Colitis. NICE technology appraisal guidance 140. London: NICE; 2008. Available from: http://www.nice.org.uk/nicemedia/pdf/TA140Guidance.pdf. Accessed January 22, 2013.
27. Parikh A, Leach T, Xu J, Feagan B. P235. Long-term clinical experience with vedolizumab (VDZ) in patients with mild to moderate ulcerative colitis (UC). J Crohns Colitis. 2012;6:Supp 1, S103.
28. Feagan B, Rutgeerts P, Sands J, et al. 943b Induction therapy for ulcerative colitis: results of GEMINI I, a randomised placebo-controlled, double-blind, multicentre phase 3 trial. Gastroenterology. 2012;142(5): S160-S161.
29. Rutgeerts P. Vedolizumab induction therapy for ulcerative colitis: results of GEMINI I, a randomized, placebo-controlled, double-blind, multicentre phase 3 trial. Gut. 2012;2012(Supp 3):A65.
30. Rutgeerts P. Vedolizumab maintenance therapy for ulcerative colitis (uc): results of GEMINI I, a randomized, placebo-controlled, double-blind, multicenter phase 3 trial. Gut. 2012;61(Supp 3):A65.
31. Reichert JM. Antibody-based therapeutics to watch in 2011. MAbs. 2011;3(1):76-99.
32. Danese S, De La Rue SA, Gasbarrini A. Antibody to α4β7 integrin for ulcerative colitis. N Engl J Med. 2005;355(11):1180.
33. Allen PB. Anti-adhesion molecules: is gut specificity the key for a good safety profile? Curr Drug Deliv. 2012;9(4):333-337.
34. Cohen RD. MLN-02 in IBD: is "super-selective" really super? Gastroenterology. 2006;130(6):1923-1924.
35. Soler D, Chapman T, Yang LL, Wyant T, Egan R, Fedyk ER. The binding specificity and selective antagonism of vedolizumab, an anti-alpha4beta7 integrin therapeutic antibody in development for inflammatory bowel diseases. J Pharmacol Exp Ther. 2009;330(3):864-875.
36. Parikh A, Fedyk E, Soler D, et al. Gastrointestinal selectivity of vedolizumab (MLN0002), a humanized monoclonal antibody to alpha4beta7 integrin: P-0025. Inflamm Bowel Dis. 2008;14:S18.
37. Fedyk ER, Wyant T, Yang LL, et al. Exclusive antagonism of the α(4) β(7) integrin by vedolizumab confirms the gut-selectivity of this pathway in primates. Inflam Bowel Dis. Epub March 14, 2012.
38. Fedyk E, Csizmadia V, Shyu W, Yang L, Wyant T, Kadambi V. The gastrointestinal-selective biologic vedolizumab does not impair immune surveillance of the central nervous system in non-human primates: O-015. Inflamm Bowel Dis. 2011;17:S4-S5.
39. Milch C, Wyant T, Xu J, Kent W, Berger J, Fox IH. P234. Vedolizumab does not reduce the CD4+:CD8+ ratio in the CSF of healthy volunteers. J Crohns Colitis. 2012;6:S102-S103.
40. Parikh A, Wyant T, Clifford D, et al. 1008 No increase in JC viremia, lymphocyte count, or circulating CD34+ hematopoietic progenitor cells after treatment with vedolizumab, a humanized monoclonal antibody to α4β7 integrin. Gastroenterology. 2010;138(5 Suppl 1):S145-S146.
41. Feagan BG, Greenberg GR, Wild G, et al. Treatment of active Crohn's disease with MLN0002, a humanized antibody to the alpha4beta7 integrin. Clin Gastroenterol Hepatol. 2008;6(12):1370-1377.